Roivant Sciences Q1 2026 Financial and Operational Update

Roivant Sciences Ltd. (NASDAQ:ROIV) posted first‑quarter results for the period ending 30 June 2026 that showed a loss of $0.26 per share, outperforming the consensus analyst estimate of a $0.30 loss. Revenue for the quarter was $1.44 million, well below the consensus forecast of $2.32 million.

Despite the revenue shortfall, the company’s share price rose approximately 2 % in pre‑market trading on Thursday, 6 August 2026, as investors noted the narrower loss and the firm’s strong cash position. Consolidated cash, cash equivalents, restricted cash and marketable securities amounted to $3.9 billion as of 30 June 2026, a figure that excludes a cash payment received from Moderna in July 2026. The company stated that this liquidity level supports its cash runway into profitability.

Clinical Development Milestones

  • Brepocitinib (dermatomyositis): Commercial preparations are progressing and the product is on track for a launch by the end of September 2026.
  • Phase 3 non‑infectious uveitis study: Top‑line data are expected in the second half of calendar year 2026.
  • Phase 3 cutaneous sarcoidosis study: First patients have been enrolled, with topline results anticipated in calendar year 2028.
  • Phase 2b/3 lichen planopilaris study (Part 1): Enrollment is progressing as reported.
  • IMVT‑1402 proof‑of‑concept trial (cutaneous lupus erythematosus): Top‑line data are projected for the second half of calendar year 2026.
  • Mosliciguat Phase 2 study (pulmonary hypertension associated with interstitial lung disease): The trial remains on schedule, with topline data also expected in the second half of calendar year 2026.

Settlement with Moderna

Genevant and Arbutus received a cash payment of $950 million from Moderna in July 2026 under a $2.25 billion settlement agreement. An additional $1.3 billion is contingent upon a favorable resolution of Moderna’s appeal.

Overall, Roivant’s Q1 performance delivered a loss beat, maintained a robust cash balance, and highlighted several upcoming clinical data readouts and a near‑term product launch, while also reporting a substantial cash inflow from a settlement with Moderna.